Development of a Microminipig Model of Atherosclerosis for the Evaluation of a HMGCR Inhibitor
CONCLUSION: A microminipig atherosclerosis model induced by HFLCD can be used in the evaluation of HMGCR inhibitors for the treatment of hypercholesterolemia and atherosclerosis.PMID:38148058 | DOI:10.21873/invivo.13415 (Source: Atherosclerosis)
Source: Atherosclerosis - December 26, 2023 Category: Cardiology Authors: Tomonobu Yamada Hiroki Kawaguchi Aki Matsuoka Kohei Akioka Naoki Miura Hiroyuki Izumi Akihide Tanimoto Source Type: research
Statin Use Reduces Radiation-Induced Stroke Risk in Advanced Nasopharyngeal Carcinoma Patients
CONCLUSIONS: Our study provides evidence supporting the beneficial effects of statin use during the CCRT period in reducing radiation-induced stroke risk among patients with advanced NPC undergoing definitive CCRT. Notably, pravastatin and atorvastatin demonstrated significant reductions in stroke occurrence. Furthermore, the findings suggest a dose-response relationship, where higher cumulative doses and greater daily dose intensity of statin use were associated with a lower risk of stroke.PMID:38142934 | DOI:10.1016/j.radonc.2023.110067 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic ...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - December 24, 2023 Category: Radiology Authors: Chuan-Yi Lin Chia-Lun Chang Kuan-Chou Lin Wan-Ming Chen Ben-Chang Shia Po-Hsiu Kuo Szu-Yuan Wu Source Type: research
Statin Use Reduces Radiation-Induced Stroke Risk in Advanced Nasopharyngeal Carcinoma Patients
CONCLUSIONS: Our study provides evidence supporting the beneficial effects of statin use during the CCRT period in reducing radiation-induced stroke risk among patients with advanced NPC undergoing definitive CCRT. Notably, pravastatin and atorvastatin demonstrated significant reductions in stroke occurrence. Furthermore, the findings suggest a dose-response relationship, where higher cumulative doses and greater daily dose intensity of statin use were associated with a lower risk of stroke.PMID:38142934 | DOI:10.1016/j.radonc.2023.110067 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic ...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - December 24, 2023 Category: Radiology Authors: Chuan-Yi Lin Chia-Lun Chang Kuan-Chou Lin Wan-Ming Chen Ben-Chang Shia Po-Hsiu Kuo Szu-Yuan Wu Source Type: research
Atorvastatin exerts dual effects of lesion regression and ovarian protection in the prevention and treatment of endometriosis
This study aimed to investigate the possible effect of atorvastatin on the ovarian endocrine function and fertility capacity in the prevention and treatment of endometriosis. Here, 5 mg/kg atorvastatin was intraperitoneally injected to the endometriosis mice once a day for consecutive fourteen days during and after the development of endometriotic implants. The results indicated that atorvastatin not only led to regression of the ectopic lesions, but also caused no discernible harm to the ovary for both the preventive and the therapeutic models. In addition, it elicited a protective effect on the ovarian reserve and fertil...
Source: European Journal of Pharmacology - December 23, 2023 Category: Drugs & Pharmacology Authors: Xian Qin Qian Wang Dongmei Xu Yixuan Sun Wandong Xu Bo Wang Zhu Yang Lijuan Hao Source Type: research
Atorvastatin exerts dual effects of lesion regression and ovarian protection in the prevention and treatment of endometriosis
This study aimed to investigate the possible effect of atorvastatin on the ovarian endocrine function and fertility capacity in the prevention and treatment of endometriosis. Here, 5 mg/kg atorvastatin was intraperitoneally injected to the endometriosis mice once a day for consecutive fourteen days during and after the development of endometriotic implants. The results indicated that atorvastatin not only led to regression of the ectopic lesions, but also caused no discernible harm to the ovary for both the preventive and the therapeutic models. In addition, it elicited a protective effect on the ovarian reserve and fertil...
Source: European Journal of Pharmacology - December 23, 2023 Category: Drugs & Pharmacology Authors: Xian Qin Qian Wang Dongmei Xu Yixuan Sun Wandong Xu Bo Wang Zhu Yang Lijuan Hao Source Type: research
Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin
ConclusionAtorvastatin doses should likely be adjusted during nirmatrelvir/ritonavir treatment. For patients on a 20-mg dose, we recommend half of the original dose. In patients taking 40 mg or more, a quarter of the dose should be taken until 2 days after discontinuation of nirmatrelvir/ritonavir. Patients receiving rosuvastatin do not need to change their treatment regimen.Trial RegistrationEudraCT number: 2021 –006634-39.DRKS00027838. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - December 19, 2023 Category: Cardiology Source Type: research
Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial
CONCLUSIONS: These findings support the hypothesis that there is an interaction between bone and cardiometabolic health and that intensive lipid lowering has a beneficial effect on bone health.PMID:38109819 | DOI:10.1016/j.atherosclerosis.2023.117425 (Source: Atherosclerosis)
Source: Atherosclerosis - December 18, 2023 Category: Cardiology Authors: Paolo Raggi Farzin M Takyar Varuna Gadiyaram Chao Zhang Arthur E Stillman Amir H Davarpanah Source Type: research
Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia
CONCLUSIONS: Shanhuang Jiangzhi tablets have a higher hypotriglyceridaemic performance than atorvastatin and an equivalent ability to lower TC and LDL-C. In addition, Shanhuang Jiangzhi tablets are a low-risk option for lowering blood lipids.PMID:38098069 | PMC:PMC10722779 | DOI:10.1186/s41043-023-00482-3 (Source: Journal of Health, Population, and Nutrition)
Source: Journal of Health, Population, and Nutrition - December 15, 2023 Category: International Medicine & Public Health Authors: GuoTong Sun XiuWen Liang Source Type: research
Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia
CONCLUSIONS: Shanhuang Jiangzhi tablets have a higher hypotriglyceridaemic performance than atorvastatin and an equivalent ability to lower TC and LDL-C. In addition, Shanhuang Jiangzhi tablets are a low-risk option for lowering blood lipids.PMID:38098069 | PMC:PMC10722779 | DOI:10.1186/s41043-023-00482-3 (Source: Journal of Health, Population, and Nutrition)
Source: Journal of Health, Population, and Nutrition - December 15, 2023 Category: International Medicine & Public Health Authors: GuoTong Sun XiuWen Liang Source Type: research
Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia
CONCLUSIONS: Shanhuang Jiangzhi tablets have a higher hypotriglyceridaemic performance than atorvastatin and an equivalent ability to lower TC and LDL-C. In addition, Shanhuang Jiangzhi tablets are a low-risk option for lowering blood lipids.PMID:38098069 | PMC:PMC10722779 | DOI:10.1186/s41043-023-00482-3 (Source: Journal of Health, Population, and Nutrition)
Source: Journal of Health, Population, and Nutrition - December 15, 2023 Category: International Medicine & Public Health Authors: GuoTong Sun XiuWen Liang Source Type: research
Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia
CONCLUSIONS: Shanhuang Jiangzhi tablets have a higher hypotriglyceridaemic performance than atorvastatin and an equivalent ability to lower TC and LDL-C. In addition, Shanhuang Jiangzhi tablets are a low-risk option for lowering blood lipids.PMID:38098069 | PMC:PMC10722779 | DOI:10.1186/s41043-023-00482-3 (Source: Journal of Health, Population, and Nutrition)
Source: Journal of Health, Population, and Nutrition - December 15, 2023 Category: International Medicine & Public Health Authors: GuoTong Sun XiuWen Liang Source Type: research
Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia
CONCLUSIONS: Shanhuang Jiangzhi tablets have a higher hypotriglyceridaemic performance than atorvastatin and an equivalent ability to lower TC and LDL-C. In addition, Shanhuang Jiangzhi tablets are a low-risk option for lowering blood lipids.PMID:38098069 | PMC:PMC10722779 | DOI:10.1186/s41043-023-00482-3 (Source: Journal of Health, Population, and Nutrition)
Source: Journal of Health, Population, and Nutrition - December 15, 2023 Category: International Medicine & Public Health Authors: GuoTong Sun XiuWen Liang Source Type: research
Retracted: Related Factors of Cerebral Hemorrhage after Cerebral Infarction and the Effect of Atorvastatin Combined with Intensive Nursing Care
Comput Math Methods Med. 2023 Dec 6;2023:9817935. doi: 10.1155/2023/9817935. eCollection 2023.ABSTRACT[This retracts the article DOI: 10.1155/2022/9546006.].PMID:38094432 | PMC:PMC10718713 | DOI:10.1155/2023/9817935 (Source: Computational and Mathematical Methods in Medicine)
Source: Computational and Mathematical Methods in Medicine - December 14, 2023 Category: Statistics Authors: Computational And Mathematical Methods In Medicine Source Type: research
